Drug Profile
Guselkumab - Janssen Biotech
Alternative Names: CNTO-1959; TREMFYA; TREMFYA ONE-PRESSLatest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator MorphoSys
- Developer Janssen Biotech; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag; MorphoSys; Taiho Pharmaceutical
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics
- Mechanism of Action Interleukin-23 subunit p19 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Erythrodermic psoriasis; Palmoplantar pustulosis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
- Preregistration Ulcerative colitis
- Phase III Crohn's disease; Psoriasis
- Phase II Giant cell arteritis; Hidradenitis suppurativa; Lupus nephritis; Systemic scleroderma
- Phase I Familial adenomatous polyposis
- Discontinued Coeliac disease; Rheumatoid arthritis
Most Recent Events
- 11 Mar 2024 Preregistration for Ulcerative colitis in USA (SC, IV)
- 19 Feb 2024 Phase-III clinical trials in Ulcerative colitis (In children, In adolescents, Treatment-experienced) in USA, China (SC) (NCT06260163),
- 22 Jan 2024 Efficacy and adverse events data form the phase IIIb trial in Plaque-psoriasis released by Janssen Pharmaceuticals